Johnson & Johnson Reports 75% Tumor Response Rate in Early-Stage Prostate Cancer Trial
Johnson & Johnson (J&J) has announced positive early-stage clinical trial results for its novel oral therapy, JNJ-6143. The treatment utilizes Regulated Induced Proximity Targeting Chimera (RIPTAC) small molecule technology to target advanced prostate cancer. The study demonstrated a significant 75% tumor response rate among participants with advanced stages of the disease. This development highlights the potential efficacy of RIPTAC technology in addressing high-need oncology indications and could represent a meaningful advancement in oral cancer therapeutics.
Tickers: $JNJ
Topics: Clinical Trials Drug Development Oncology Prostate Cancer